Genmab and Lundbeck implement sustainability goals in executive incentive programs

Genmab and Lundbeck currently belong in the exclusive club of C25 companies that are integrating ESG indicators into their management incentive compensation plans.

Lundbeck CEO Deborah Dunsire | Photo: Gregers Tycho/ERH

Prominent pharmaceutical industry figures like Jan van de Winkel and Deborah Dunsire from Genmab and Lundbeck, respectively, are joining top executives at Novo Nordisk and Novozymes in a small but exclusive club of C25 companies which integrate ESG indicators into their management incentive schemes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs